Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody

Ted R Mikuls, James Robert O'Dell, J. A. Stoner, L. A. Parrish, W. P. Arend, J. M. Norris, V. M. Holers

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Objective. To examine the association of treatment response and disease duration with changes in rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody levels among patients with rheumatoid arthritis (RA). Methods. The study sample included 66 RA patients who completed double-blind, randomized clinical protocols and for whom baseline and followup serum samples were available. Anti-CCP and RF levels were measured using commercially available assay kits. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to describe the association of response and disease duration with declines in antibody levels. Results. Patients had a mean ± SD age of 49.9 ± 12.0 years and were predominantly female (n = 51; 77%). The mean ± SD duration between the times at which the baseline and followup serum samples were obtained was 13.7 ± 8.6 months. Among the 64 subjects will positive antibody at baseline, 33 (52%) experienced a ≥25% reduction in the anti-CCP antibody level during the course of treatment, and 35 patients (55%) had a ≥25% reduction in RF. After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration (≤12 months) was significantly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no association with treatment response was observed. Conversely, treatment response was the only significant determinant of a decrease in MF levels (OR 3.6, 95% CI 1.2-10.4). Conclusion. Shorter disease duration predicts greater declines in anti-CCP antibody levels with treatment in RA. Although treatment response is a robust determinant of a decrease in RF, it does not appear to be associated with declines in the anti-CCP antibody level.

Original languageEnglish (US)
Pages (from-to)3776-3782
Number of pages7
JournalArthritis and rheumatism
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Rheumatoid Factor
Immunoglobulin M
Rheumatoid Arthritis
Antibodies
Serum
Odds Ratio
Confidence Intervals
Therapeutics
cyclic citrullinated peptide
Clinical Protocols

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. / Mikuls, Ted R; O'Dell, James Robert; Stoner, J. A.; Parrish, L. A.; Arend, W. P.; Norris, J. M.; Holers, V. M.

In: Arthritis and rheumatism, Vol. 50, No. 12, 01.12.2004, p. 3776-3782.

Research output: Contribution to journalArticle

@article{d2702567c53d4e33b69d6b33a7a5235f,
title = "Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody",
abstract = "Objective. To examine the association of treatment response and disease duration with changes in rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody levels among patients with rheumatoid arthritis (RA). Methods. The study sample included 66 RA patients who completed double-blind, randomized clinical protocols and for whom baseline and followup serum samples were available. Anti-CCP and RF levels were measured using commercially available assay kits. Odds ratios (ORs) and 95{\%} confidence intervals (95{\%} CIs) were used to describe the association of response and disease duration with declines in antibody levels. Results. Patients had a mean ± SD age of 49.9 ± 12.0 years and were predominantly female (n = 51; 77{\%}). The mean ± SD duration between the times at which the baseline and followup serum samples were obtained was 13.7 ± 8.6 months. Among the 64 subjects will positive antibody at baseline, 33 (52{\%}) experienced a ≥25{\%} reduction in the anti-CCP antibody level during the course of treatment, and 35 patients (55{\%}) had a ≥25{\%} reduction in RF. After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration (≤12 months) was significantly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95{\%} CI 1.0-8.8), and no association with treatment response was observed. Conversely, treatment response was the only significant determinant of a decrease in MF levels (OR 3.6, 95{\%} CI 1.2-10.4). Conclusion. Shorter disease duration predicts greater declines in anti-CCP antibody levels with treatment in RA. Although treatment response is a robust determinant of a decrease in RF, it does not appear to be associated with declines in the anti-CCP antibody level.",
author = "Mikuls, {Ted R} and O'Dell, {James Robert} and Stoner, {J. A.} and Parrish, {L. A.} and Arend, {W. P.} and Norris, {J. M.} and Holers, {V. M.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/art.20659",
language = "English (US)",
volume = "50",
pages = "3776--3782",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody

AU - Mikuls, Ted R

AU - O'Dell, James Robert

AU - Stoner, J. A.

AU - Parrish, L. A.

AU - Arend, W. P.

AU - Norris, J. M.

AU - Holers, V. M.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Objective. To examine the association of treatment response and disease duration with changes in rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody levels among patients with rheumatoid arthritis (RA). Methods. The study sample included 66 RA patients who completed double-blind, randomized clinical protocols and for whom baseline and followup serum samples were available. Anti-CCP and RF levels were measured using commercially available assay kits. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to describe the association of response and disease duration with declines in antibody levels. Results. Patients had a mean ± SD age of 49.9 ± 12.0 years and were predominantly female (n = 51; 77%). The mean ± SD duration between the times at which the baseline and followup serum samples were obtained was 13.7 ± 8.6 months. Among the 64 subjects will positive antibody at baseline, 33 (52%) experienced a ≥25% reduction in the anti-CCP antibody level during the course of treatment, and 35 patients (55%) had a ≥25% reduction in RF. After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration (≤12 months) was significantly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no association with treatment response was observed. Conversely, treatment response was the only significant determinant of a decrease in MF levels (OR 3.6, 95% CI 1.2-10.4). Conclusion. Shorter disease duration predicts greater declines in anti-CCP antibody levels with treatment in RA. Although treatment response is a robust determinant of a decrease in RF, it does not appear to be associated with declines in the anti-CCP antibody level.

AB - Objective. To examine the association of treatment response and disease duration with changes in rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody levels among patients with rheumatoid arthritis (RA). Methods. The study sample included 66 RA patients who completed double-blind, randomized clinical protocols and for whom baseline and followup serum samples were available. Anti-CCP and RF levels were measured using commercially available assay kits. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to describe the association of response and disease duration with declines in antibody levels. Results. Patients had a mean ± SD age of 49.9 ± 12.0 years and were predominantly female (n = 51; 77%). The mean ± SD duration between the times at which the baseline and followup serum samples were obtained was 13.7 ± 8.6 months. Among the 64 subjects will positive antibody at baseline, 33 (52%) experienced a ≥25% reduction in the anti-CCP antibody level during the course of treatment, and 35 patients (55%) had a ≥25% reduction in RF. After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration (≤12 months) was significantly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no association with treatment response was observed. Conversely, treatment response was the only significant determinant of a decrease in MF levels (OR 3.6, 95% CI 1.2-10.4). Conclusion. Shorter disease duration predicts greater declines in anti-CCP antibody levels with treatment in RA. Although treatment response is a robust determinant of a decrease in RF, it does not appear to be associated with declines in the anti-CCP antibody level.

UR - http://www.scopus.com/inward/record.url?scp=10444250299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444250299&partnerID=8YFLogxK

U2 - 10.1002/art.20659

DO - 10.1002/art.20659

M3 - Article

C2 - 15593224

AN - SCOPUS:10444250299

VL - 50

SP - 3776

EP - 3782

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -